- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05512091
Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use (DuCATA_GAMCaT)
June 28, 2023 updated by: Cristina Martínez Martínez
Characterization of the Pattern of Consumption and Withdrawal Syndrome From Dual Cannabis and Tobacco Use in People With Cannabis Use Disorder Who Initiate Dishabituation Treatment (DuCATA_GAM-CAT)
Aims: To characterize the pattern of cannabis and tobacco use and withdrawal symptoms in people who start treatment for cannabis use disorders (exclusive cannabis, concurrent and/or simultaneous with various tobacco products) through an aplication game and considering the type of users.
Methodology: Mixed-methods research composed of three studies.
Study I: qualitative participatory action study aimed at exploring the experiences and preferences of the cannabis users on the use of apps.
This information will be instrumental in the co-design of the app.
Study II: prospective longitudinal study aimed to establish consumption patterns and transitions between substances and to validate the scale of cannabis withdrawal symptoms in the Spanish population.
Sample size: expected RR=1.20,
α =0.05, β= 0.20, losses= 20% (n=282).
Study III: qualitative study to explore participants' experiences during the process of quitting cannabis and / or tobacco.
Expected results: Characterization and prediction of variables that influence cannabis and tobacco cessation/ reduction and describe withdrawal symptoms according to consumption patterns with aim of improving the design of future interventions.
Study Overview
Status
Not yet recruiting
Study Type
Observational
Enrollment (Estimated)
282
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Cristina Martínez Martínez, PhD
- Phone Number: 932607335
- Email: cmartinez@iconcologia.net
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Smokers under treatment for cannabis substance abuse from the province of Barcelona in Catalonia (Spain)
Description
Inclusion Criteria:
- Smokers (at least 1cig./week)
- Undertreatment for Cannabis
- >=18 years-old
- Under clinical follow-up
- Informed consent
- Have a Smartphone
Exclusion Criteria:
- Severe cognitive impairment
- 3-month follow-up not guaranteed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cannabis use
Time Frame: Change between baseline and 6 weeks follow-up
|
Number of participants that use several cannabis products (hashish, marijuana, etc.)
|
Change between baseline and 6 weeks follow-up
|
|
Tobacco use
Time Frame: Change between baseline and 6 weeks follow-up
|
Number of participants that use several type of tobacco product/s
|
Change between baseline and 6 weeks follow-up
|
|
Abstinence from cannabis
Time Frame: Change between baseline and 6 weeks follow-up
|
If a participant reduces or quits their cannabis use, we will ask for their presence of 16 withdrawal symptoms.
Each symptom is scored from 0 (minimum) to 3 (maximum).
Higher scores mean a worse outcome.
|
Change between baseline and 6 weeks follow-up
|
|
Abstinence from tobacco
Time Frame: Change between baseline and 6 weeks follow-up
|
If a participant reduces or quits their tobacco use, we will ask for their presence of 6 withdrawal symptoms using the Fagerström test.
The test has a minimum score of 0 and a maximum of 10.
Higher scores mean a worse outcome.
|
Change between baseline and 6 weeks follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motivation to quit
Time Frame: Baseline
|
Using a Likert scale randing from 0 to 10 (0=totally unmotivated and 10= totally motivated)
|
Baseline
|
|
Psychological assessment
Time Frame: Baseline
|
States of change or readiness to quit cannabis and tobacco according to Prochaska and Di Clemente's model (pre-contemplative, contemplative, prepared, action and maintenance.
|
Baseline
|
|
Self-perceived health status
Time Frame: Baseline
|
Will be assessed based on "How would you say your general health is?" (excellent, very good, good, fair, very fair, poor)
|
Baseline
|
|
Social and cultural factors
Time Frame: Baseline
|
Questions related to their social circle/network (friends and colleagues) and social climate overall
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2023
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
May 6, 2022
First Submitted That Met QC Criteria
August 20, 2022
First Posted (Actual)
August 23, 2022
Study Record Updates
Last Update Posted (Actual)
July 3, 2023
Last Update Submitted That Met QC Criteria
June 28, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DUCATA_GAM-CaT_REF:2020I034
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
Loma Linda UniversityUniversity of California, San Francisco; Riverside University Health System...RecruitingTobacco Use | Tobacco Use Cessation | Tobacco Use in ChildbirthUnited States
-
University of Mississippi Medical CenterNot yet recruitingTobacco Cessation
-
University of California, San FranciscoTobacco Related Disease Research ProgramRecruitingTobacco Cessation | Tobacco Use | Tobacco Use Cessation | Tobacco Dependence | Tobacco AbstinenceUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Duke UniversityCompletedSmokeless Tobacco CessationUnited States
-
University of FloridaRecruitingTobacco Use | Nicotine UseUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedTobacco Product Beliefs and UseUnited States